A small pilot trial in the United States has found that combining a brief form of couples therapy with MDMA can produce substantial improvements in both PTSD symptoms and relationship satisfaction among veterans and their partners. The study delivered two day-long MDMA dosing sessions to the diagnosed veteran, while the partner attended all sessions but did not receive the drug.
PTSD is a mental health condition triggered by traumatic experiences, with symptoms including flashbacks, nightmares and severe anxiety. When PTSD afflicts a veteran, the resulting strain can extend into the intimate relationship, undermining communication and a sense of safety between partners.
Psychologists have long developed cognitive-behavioural conjoint therapy to address both individual trauma symptoms and relational distress. In this approach, the person with PTSD and their partner attend sessions together to learn about trauma’s impact on their relationship, improve communication and challenge unhelpful trauma-related thoughts.
While this therapy can reduce PTSD symptoms, its gain in relationship satisfaction tends to be more modest, with the brief eight-session version showing similar PTSD benefits but smaller relational improvements.
To boost relationship effects, researchers have explored MDMA, a psychoactive drug that can enhance mood, empathy and social connection in a therapeutic setting. A 2026 trial analysis suggested MDMA-assisted psychotherapy helps relieve chronic PTSD symptoms by fostering positive mood changes that aid recovery.
In a shift from earlier work where MDMA was given to both partners, the new study designed a scenario in which only the veteran with PTSD would receive the medication. The aim was to determine whether a shortened therapy protocol combined with MDMA for the patient could yield both personal symptom relief and relational gains, while remaining practical within clinical and insurance frameworks.
The researchers recruited eight couples from the Veterans Affairs San Diego Healthcare System. In each couple, the veteran met the PTSD diagnostic criteria, while the partner did not. Veterans averaged around 46 years old; partners around 43.
Over roughly seven weeks, participants followed the eight-session brief cognitive-behavioural conjoint therapy protocol, augmented by two day-long MDMA dosing sessions for the veteran. An introductory preparation session preceded the MDMA sessions.
During the first MDMA session, the veteran received an initial 80-milligram dose, with an optional 40-milligram supplementary dose a few hours later. The second session involved a higher initial dose of 100 milligrams, again with an optional 40-milligram supplement. The partner joined the room for the final one to two hours of these sessions, but did not receive MDMA.
The morning after each MDMA session, the couples attended an integration session. The veteran shared their experiences and insights, while the partner spoke about their emotional responses. Therapists incorporated strategies from integrative behavioural couple therapy to help the partners build empathy and move away from rigid conflict patterns.
Outcomes were assessed using clinical interviews for PTSD severity and self-report measures of relationship satisfaction. Assessments occurred at baseline, during treatment, at the end of treatment and at three and six months thereafter, with analyses controlling for initial scores.
At baseline, veterans averaged a PTSD severity score of 39.1 on a standard scale. By the end of the treatment, the average score had fallen by 16.1 points, indicating a large reduction in symptom severity.
Five of the eight veterans exhibited a clinically meaningful treatment response; among these, three no longer met PTSD diagnostic criteria and two achieved full symptom remission by the study’s end.
Relationship satisfaction also improved for both members of the couples. Veterans’ scores rose by an average of 27.9 points, while partners’ scores increased by 19.8 points on a measure of relationship happiness and quality.
From the six couples who started with clinical relationship distress, four veterans and four partners reached non-distressed levels by the conclusion of the treatment. One partner who began in the non-distressed range experienced a decline in relationship satisfaction over the course of the study.
During the three- and six-month follow-up period, there was a modest rebound in PTSD symptoms of about 6.3 points on average, and relationship satisfaction scores drifted downward slightly, though they remained higher than baseline.
The treatment was generally well tolerated, with no serious adverse events reported. The most common MDMA-related effects were headaches, a sensation of warmth, temporary increases in blood pressure and nausea. All eight couples completed the full course of treatment, indicating the approach was acceptable to participants.
As with any early research, several caveats apply. The study was a small pilot trial with eight couples and lacked a control group that would clarify how much of the improvement derived from MDMA versus the intensive therapy alone.
Participants were predominantly white, heterosexual and highly educated, which may limit the generalisability of the findings to other demographic groups or those with fewer resources.
The partial relapse of symptoms and relational distress during the follow-up period suggests that an eight-session model might not yield permanent changes for everyone. Veterans with more complex psychiatric histories could require longer treatment or extended integration support to maintain gains.
The study, “Healing together: Results from a pilot trial of 3,4-Methylenedioxymethamphetamine-enhanced cognitive-behavioural conjoint therapy for posttraumatic stress disorder,” was authored by Leslie A. Morland, Chandra E. Khalifian, Dimitri Perivoliotis, Bettye Chargin, Al Alam, Tamara R. Wachsman, Dhakshin Ramanathan, Andrew W. Bismark, Christopher Stauffer, Anne C. Wagner, Abigail C. Angkaw and Kayla C. Knopp.
